Stevanato Group S P A Stock Price, News & Analysis

Stevanato Group (NYSE: STVN), a leading provider of drug containment, drug delivery, and diagnostic solutions, has scheduled its Fourth Quarter and Fiscal Year 2024 financial results announcement for March 6, 2025, at 6:30 a.m. ET.

The company will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss the results. Management will reference a slide presentation available on the company's Investor Relations website. Participants can pre-register for immediate access to the call, while a live webcast will also be available. The webcast recording will be archived for three months on the company's Investor Relations section.

Stevanato Group (NYSE: STVN), a global leader in drug containment and delivery solutions for pharmaceutical, biotechnology, and life sciences industries, has announced its participation in the CJS Securities 25th Annual "New Ideas for the New Year" Investor Conference. The presentation is scheduled for Tuesday, January 14, 2025, at 8:00 a.m. ET.

The company will provide a live webcast of the event through their website at www.stevanatogroup.com in the "Investors" section. Interested parties who cannot attend the live presentation can access a replay of the webcast, which will remain available for approximately 90 days following the event.

Stevanato Group (NYSE: STVN), a global leader in drug containment and delivery solutions, has announced its participation in three major investor conferences. The company will join the UBS Global Healthcare Conference in California on November 12, 2024, the Jefferies London Healthcare Conference on November 19, 2024, and the Citi 2024 Global Healthcare Conference in Miami on December 3, 2024.

Live webcasts of all presentations will be available on the company's website under the Investors section, with replays accessible for approximately 90 days following each event.

Stevanato Group (NYSE: STVN) reported Q3 2024 financial results with revenue increasing 2% to €277.9 million. High-value solutions represented 36% of total revenue. The company maintained its FY2024 revenue guidance of €1,090-1,110 million but lowered adjusted EBITDA guidance to €257-263 million and adjusted EPS to €0.47-0.49.

The Biopharmaceutical and Diagnostic Solutions segment grew 6% to €233.0 million, while Engineering segment declined 15% to €44.8 million. Gross profit margin decreased to 26.8% from 30.5% year-over-year, impacted by vial destocking and startup costs at the U.S. facility.

Stevanato Group (NYSE: STVN) has announced the expansion of its Vertiva® platform to include a 10mL option for on-body drug delivery. The platform offers a pre-filled and pre-loaded solution suitable for highly viscous biological drugs. Vertiva® features a single-use pod with a pre-filled cartridge and a reusable smart controller, allowing for versatile dosing profiles and easy home-based treatment.

The system's design simplifies treatment initiation and has shown positive results in a recent wearability study. It can record patient usage data and transfer it via Bluetooth to digital health applications. The platform's two-part system enhances sustainability by reducing electronic waste. Stevanato Group will collaborate with Thermo Fisher Scientific to bring Vertiva® 10mL to market, offering integrated capabilities from drug development to final packaging.

Stevanato Group (NYSE: STVN), Gerresheimer AG (MDAX: GXI), and SCHOTT Pharma AG & Co. KGaA (MDAX: 1SXP) have formed the 'Alliance for RTU' to promote the adoption of Ready-to-Use (RTU) vials and cartridges in the pharmaceutical industry. This strategic alliance aims to share expertise on high-quality sterile primary packaging with pharmaceutical companies, CMOs, and CDMOs.

The alliance highlights the advantages of RTU configurations over conventional bulk packaging, including reduced operational risks, enhanced flexibility, increased efficiency, and lower total cost of ownership. RTU technology can help streamline processes, increase productivity, and reduce contamination risks while easing EU GMP Annex 1 compliance.

The Alliance for RTU will create an open expert platform to help industry manufacturers learn about the benefits of RTU processes and products, supporting the transition to efficient filling systems for both clinical applications and commercial use.

Stevanato Group (NYSE: STVN), a leading provider of solutions for the pharmaceutical, biotechnology, and life sciences industries, has announced its participation in two upcoming investor conferences. The company will present at:

• The Morgan Stanley Healthcare Conference in New York on September 6, 2024, at 7:00 a.m. ET
• The Bank of America Global Healthcare Conference in London on September 18, 2024, at 2:10 p.m. BST

Live webcasts of both events will be available on the company's website under the 'Investors' section, with replays accessible for approximately 90 days after each event.

Stevanato Group (NYSE: STVN) reported its Q2 2024 financial results, with revenue increasing 2% to €259.6 million. The Biopharmaceutical and Diagnostic Solutions (BDS) Segment grew 9%, offsetting a 26% decline in the Engineering Segment. High-value solutions represented 40% of total revenue. Diluted EPS was €0.08, and adjusted diluted EPS was €0.09. The company updated its FY 2024 guidance, now expecting revenue between €1,090-1,110 million, adjusted EBITDA of €264-272 million, and adjusted diluted EPS of €0.48-0.50.

Challenges in the Engineering Segment, including project delays and higher costs, led to the guidance revision. The BDS Segment faced temporary inefficiencies due to new facility start-ups and customer vial destocking. Despite these challenges, the company remains focused on executing its strategic priorities and capitalizing on favorable long-term trends in biologics and high-value solutions.

Stevanato Group (NYSE: STVN), a leading provider of drug containment, delivery, and diagnostic solutions, has announced its plans to release second quarter 2024 financial results on August 6, 2024, at 6:30 a.m. ET. The company will host a conference call and webcast at 8:30 a.m. ET on the same day to discuss the results. Management will refer to a slide presentation available on the company's website. Participants can pre-register for the call or dial in directly. A live webcast will be available, and the call will be archived for three months on the company's Investor Relations website.